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Introduction
Bladder cancer is an actual problem of modern oncou-
rology, because of high rates of prevalence, recurrence, pro-
gression, and a major burden on the medical healthcare sys-
tem and the economy. In 2015 incidence of bladder cancer 
ranked ninth and mortality thirteenth worldwide. It ranked 
the highest in high-sociodemographic index countries at 
position eighth for incidence and eleventh for cancer deaths 
[1]. Bladder cancer is divided into two main categories: 
non-muscle-invasive bladder cancer (NMIBC) which con-
stitutes 75% and muscle-invasive bladder cancer (MIBC) 
which makes up 25% [2]. The perfect method of laboratory 
diagnosis of bladder cancer must be extremely sensitive and 
specific, easily reproducible, inexpensive, suitable for pri-
mary diagnosis, screening, and monitoring of patients, to 
detect recurrence on time [3]. 
Currently, the main diagnostic tool for the detection of 
bladder cancer remains cystoscopy, which is an effective but 
invasive method of diagnostics. Even after a flexible cystos-
copy, we have pain during urination in 50% of cases, uri-
nary frequency in 37%, visible hematuria at 19% of patients, 
and infection in 3% of cases [4]. Sensitivity and specificity 
of cystoscopy ranged from 62 to 84% and 43 to 98%, re-
spectively, depending on the type, stage, and grading of the 
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Abstract
Background: The perfect method for laboratory diagnosis of bladder cancer should have high sensitivity and specificity, should be easily reproducible, 
inexpensive, be suitable for primary diagnosis, screening, and follow-up of patients, for timely detection of recurrence. In clinical practice, for bladder 
cancer diagnostics have been used the following markers: UBC, BTA, “ImmunoCyt”, NMP22, “UroVision», and others.  Each method has relative 
advantages and disadvantages.  The study has demonstrated an influence on the test result of the histological structure and grade of the tumor, presence 
of hematuria, urolithiasis, chronic inflammatory malignancies, recent surgical procedures on the urinary tract. Apparently, the use of a palette of markers 
in connection with imaging techniques will increase the diagnostic capabilities, but it is still not clear which elements should be present in such palette.
Conclusions: At present, basic diagnostic methods for bladder cancer remain: USG, MRI, CT, and endoscopic methods. The laboratory methods that 
exist are not informative enough. Each marker has serious restrictions, but possibly the complex application will allow increasing the diagnostic value in 
the future, therefore it is necessary to develop new markers of bladder cancer or to study the results of the complex application of several known markers 
to increase the value of the laboratory diagnosis of primary bladder cancer and recurrent.
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tumor, it has a low sensitivity for carcinoma in situ (CIS) 
[5]. Long-term observation thereby remains the keystone of 
long-term management, and cystoscopy for over 80 years 
remains the gold standard. However, cystoscopic access is 
economically expensive for the medical healthcare system 
and burdensome for patients, therefore, for decades, there 
has been a search for non-invasive urine biomarkers that 
can match or even improve the specificity and sensitivity of 
cystoscopy. However, current guidelines do not recommend 
the use of urinary biomarkers in the management of bladder 
cancer patients [6].
The use of urine-based biomarkers to detect bladder 
cancer seems to be an attractive alternative. Urinary bio-
markers are in direct contact with the bladder and can come 
in a variety of forms, such as proteins, metabolites, deoxy-
ribonucleic acid (DNA), different types of ribonucleic acid 
(RNA), and single nucleotide polymorphisms. The exis-
tence of variations in the expression of those molecules may 
be related to bladder cancer [7].
For the diagnosis of bladder tumors, cytological meth-
ods and different tumor markers are used. There are several 
classifications of tumor markers. According to the purpose 
of the research, markers are divided: which are used in the 
primary diagnosis and for the prognosis of recurrences, pro-
gression, and tumor metastasis [8]. Depending on the type 
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of material studied, the following markers are distinguished: 
urinary, serum, and tissue. The evaluation of markers in 
urine is of major clinical interest, because the given method 
is non-invasive, reduces the number of cystoscopes, and al-
lows obtaining sufficient material for investigation [9].
However, in a lot of biomarker studies, we see displace-
ment due to the severe and advanced cases of disease which 
probably rise apparent sensitivity (the percent of correctly 
identified cases) and inclusion of healthful volunteers which 
is probably to rise evident specificity (the percent of cor-
rectly identified controls), or the use of patients with big 
primary tumors when the aim is to discover slight recurrent 
tumors [10]. Another high pitfall in the measuring of uri-
nary biomarkers for bladder cancer is haematuria: haema-
turia is a symptom and sign of bladder cancer but is not the 
biological reason for bladder cancer. Thereby, each protein 
represented in the blood can appear to act as a biomarker in 
case-control studies where haematuria is not matched, but 
will not be bladder cancer-specific [11].
urinary cytology
Urine cytological investigation is the standard laborato-
ry method for diagnosing bladder tumors with which other 
methods are compared. Cytology is used in clinical practice, 
it is a non-invasive method where voided or obtained with 
special instrument urine is examined for exfoliated cancer 
cells. We can mention as summary data that the diagnos-
tics of cytology is not significant and constitutes in medium: 
specificity 40 – 44% and sensitivity 30 – 35%. There is a cor-
relation between sensitivity and the degree of tumor differ-
entiation: G1 – 13 – 16%; G2 – 31 – 36%; G3 – 70 – 84%, Tis 
– 92 – 94%, i.e. the more aggressive is the tumor, the greater 
is the possibility of detection, but to establish the diagnosis 
it is necessary to have a well-trained cytologist [12, 13].
Ajit D. et al. reported results of cytological investigations 
in 951 patients with bladder cancer, 1831 samples were per-
formed. The histopathological examination of the bladder 
bioptate was performed as a control method. There were 
173 false-negative and 6 false-positive results. The general 
specificity was 82% and the sensitivity – 96%. The main 
cause of false-negative results was related to high tumor 
differentiation, when the sensitivity of the method is lower. 
False-positive results can be explained by changes related 
to chronic inflammation of the urothelium [14]. Another 
example: Lokeshwar V. et al. studied 690 patients with the 
single episode of macrohematuria. All patients underwent 
urethrocystoscopy, ultrasound scan (USG), urine insemi-
nation, blood analysis, and urine cytology. Results: general 
sensitivity was – 40.2%, specificity – 98.7%, positive predic-
tive value – 81.4%. The authors signed that with the help of 
the cytological examination it was not possible to highlight 
formations that would not be diagnosed with routine meth-
ods [15].
In 2016 the Paris Working Group published the stan-
dardized system for reporting by category the diagnosis of 
urinary cytology, which was validated in several retrospec-
tive studies [16, 17]. The Paris system includes the following 
groups [18]:
•	 Adequacy of urine specimens (Adequacy);
•	 Negative for high-grade urothelial carcinoma (Nega-
tive);
•	 Atypical urothelial cells (AUC);
•	 Suspicious for high-grade urothelial carcinoma (Sus-
picious);
•	 High-grade urothelial carcinoma (HGUC);
•	 Low-grade urothelial neoplasia (LGUN).
Tumor markers
There are several markers that are used in the diagnosis 
of bladder cancer (Table 1). In clinical practice, the follow-
ing testing systems have received the most widespread: UBC 
cancer antigen, BTA, NMP-22, UroVision, ImmunoCyt, 
CYFRA 21-1, CK 20, and others.
Bladder cancer antigen (UBC) is a soluble fragment of 
cytokeratins 8 and 18 (intermediate microfilaments of epi-
thelial cells). With the active proliferation and malignant 
cell transformation, cytokeratin expression increases [19]. 
The discriminant level is 32 μg/L. The sensitivity of the 
method is 60-78% for primary patients, the specificity can 
reach 95%. The correlation between the stage of the tumor 
Table 1
Sensitivity and specificity of diagnostic tests for bladder cancer
Name of the test Marker Sensitivity % Specificity % Comments
Urinary cytology Cytological examination of urine 40 - 44 30 - 35 Control method
UBC Cytokeratin levels 8 and 18 54 97 Low sensitivity
BTA Antigen, linked to urinary bladder cancer 50 - 80 50 - 75 Diagnostic significance decreases in the 
presence of urinary tract diseases
NMP-22 Nuclear matrix protein 50 - 90 70 - 85 Low sensitivity in invasive non-muscular tumors 
(50%) to invasive (90%), the high negative 
predictive value
ImmunoCyt High molecular weight carcinoembry-
onic antigens and mucins
50 - 95 60 - 85 High sensitivity to well-differentiated tumors
UroVision In situ fluorescence hybridization 70 - 100 66 - 93 Costly and time-consuming method
CYFRA 21.1 Cytokeratin levels 19 73 41 Low specificity
CK 20 Cytokeratin levels 20 85 76
Survivin Survivin levels 82 90 The costly and time-consuming analysis process
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process and the proliferative activity of the tumor cells was 
observed. According to Todenhofer T. et al., who analyzed 
the results of the diagnosis of bladder cancer in 177 patients, 
at a discriminatory level of 12.3 ng/ml, the sensitivity of the 
method was 57.8% and the specificity – 66.7% [20]. For the 
bladder cancer antigen rapid test (UBC-rapid test), Ecke et 
al. in 2017 reported: sensitivity of 87% for detecting carcino-
ma in situ, 71% for high-grade non-muscle invasive bladder 
cancer, 60% for high-grade muscle invasive bladder cancer, 
and 30% for low-grade non-muscle invasive bladder cancer 
[21].
The bladder tumor antigen (BTA) is a single-chain pro-
tein, which is associated with human complement factor H 
(hCFHrg), with the property of a germ factor. BTA is deter-
mined in urine, discriminatory level 14 Un/ml. Leyh H. et 
al. studied 414 patients with invasive non-muscular tumors 
of the bladder. The sensitivity of the BTA test was 70%, spec-
ificity – 90%. A correlation was established between sensi-
tivity and tumor degree of differentiation: an increase was 
marked in sensitivity from 17% in G1 to 64% in G2 and up 
to 92% in G3. The sensitivity of the method in recurrences 
was 67%. The sensitivity of the method also increases with 
increasing stage of the pathology: from 50% to 90%. For ex-
ample, in stage Ta, the sensitivity of the BTA test was 53.8%, 
but in T1 – already 76% [22, 23].
The quantitative BTA (BTA TRAK®) test is performed 
in a specialized laboratory, whereas the qualitative BTA 
(BTA stat®) is a point-of-care test with an immediate result 
(Polymedco Inc., Cortlandt Manor, New York, USA). They 
have a sensitivity of 65% versus 64%, and a specificity of 74% 
versus 77%, respectively [24, 25]. However, the specificity of 
both of these tests is significantly decreased since false posi-
tives have been noted to occur due to the presence of human 
complement factor H-related protein in blood. Hematuria 
can be presented in different urological malignancies, such 
as urolithiasis, inflammation, recent use of instrumentation, 
other genitourinary malignancies, and intravesical Bacillus 
Calmette Guérin (BCG) therapy which causes local inflam-
mation [24-27].
The European Association of Urology examines the 
diagnostic values of each of the proposed test systems. By 
combining the most preferred properties are considered: 
”ImmunoCyt”, NMP-22, and ”UroVision” [28]. 
Nuclear matrix protein 22 (NMP22) may be identified 
in urine as a biomarker of the death of the urothelial cells. 
This marker is often elevated in the urine of patients with 
bladder cancer and can thus be used in the finding of this 
disease. The NMP22®BladderChek® and NMP22®BC test kit 
is qualitative and quantitative enzyme immunoassay tests, 
respectively (originally Matritech Inc., Newton, MA, USA). 
The sensitivity of 69% and specificity of 77% quantitative 
NMP22 BC test kit is compared to a sensitivity of 58% and 
a specificity of 88% for the qualitative NMP22 test [25, 
29]. However, are common false-positive results, because 
NMP22 is emitted from apoptotic cells which also occur in 
case of hematuria, infection, or inflammation [25, 30-32]. Its 
discriminatory level is 10 Un/ml. One of the benefits of the 
given test is a high negative predictive value. This marker is 
not widespread due to insufficient diagnostic value, but it is 
considered that its diagnostic role may be more significant 
when used in the palette of bladder cancer markers [33].
ImmunoCyt™/uCyt+™ is an immunocytochemical test 
that utilizes fluorescently marked antibodies that are guid-
ed against three antigens:  two mucins which are specifi-
cally detected on malignant exfoliated urothelial cells and 
a glycosylated form of carcinoembryonic antigen [34]. This 
method has a high sensitivity in well-differentiated tumors 
and is less affected by concomitant inflammatory changes 
of the urinary tract, more preferably to be used in the pri-
mary diagnosis. Sensitivity is 50-95%, specificity – 60-85% 
[35]. The sensitivity of this test is higher than cytology, but 
the specificity is lower [36]. False positives are seen during 
infection or inflammation and there is poor sensitivity in 
T2 bladder cancers. Moreover, interobserver variability ex-
ists; trained cytopathologists are therefore necessary [37]. It 
is only approved for the surveillance of bladder cancer pa-
tients [38].
Widespread received the method for detecting chromo-
somal rearrangements using in situ fluorescence hybrid-
ization (FISH). FISH is a technique that uses fluorescently 
labeled deoxyribonucleic acid (DNA) probes to assess cells 
for genetic alterations [39]. Exfoliated urothelial cells are 
detected in voided urine, are hybridized on a slide. They are 
further examined for chromosomal aberrations which are 
found in bladder cancer: aneuploidy of chromosomes 3, 7, 
and 17, and a loss of locus 9p21 [38, 40]. In a meta-analysis, 
the specificity of the test was stated to be 83%, and the sen-
sitivity to be 72% in the context of equivocal cytology [41]. 
Another recent meta-analysis of studies of UroVysion™ has 
calculated its sensitivity and specificity in detecting bladder 
cancer at 63% and 87%, respectively [39]. The lack of sensi-
tivity for low-grade bladder cancers remains [42].
Jeong S. et al. analyzed the results of the CYFRA 21-1, 
NMP22, UBC and FDP tests in 250 patients. Of these, 54 
were diagnosed with bladder cancer. The control group 
consisted of 196 patients with inflammatory diseases of the 
urinary tract, benign prostatic hyperplasia, hematuria of 
non-tumor etiology. The level of the studied markers was 
significantly higher in the study group than in the control 
group. The best results were observed with CYFRA 21-1 and 
NMP 22 [43]. 
Ludecke G. et al. investigated the influence of hematuria 
intensity on the level of UBC, NMP22, and BTA markers. 
As study material, they used freshly heparinized blood ti-
trated in the urine of conventionally healthy people at dif-
ferent concentrations. The level of UBC and NMP22 did not 
increase at different intensities of macrohematuria. The BTA 
test showed the worst results: false-positive results were re-
corded in the presence of over 150 red blood cells in the 
visual field [44].
The combination of markers increases the diagnostic 
value compared to using each separate marker. Todenhöfer 
T. et al. studied the results of the application: urine cyto-
logical examination, FISH, ImmunoCyt, and NMP22. 
Diagnostic data from 808 primary care patients and 505 pa-
tients with non-invasive muscle bladder cancer recurrence 
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were analyzed. The complex application of these markers 
has demonstrated a high negative predictive value, which 
potentially makes it possible to use them as an additional 
control method between programmed cystoscopes [45].
Table 1 presents generalized data on sensitivity and 
specificity of different markers compared to cytological ex-
amination of urine.
If the main goal is to avoid unnecessary cystoscopies, 
rather than looking for markers with high sensitivity and 
specificity, the focus should be on identifying a marker with 
a very high negative predictive value. A test capable of pre-
dicting the absence of the tumor will be of great use in daily 
clinical practice [46]. Promising new urinary biomarkers, 
which evaluate several targets, have been tested in multi-
center prospective studies with a very high negative predic-
tive value [47, 48]. More studies are needed to obtain truth-
ful information about diagnostic markers of bladder tumors 
for their implementation and use in daily practice. 
Conclusions
It should be noted that currently the basic methods, 
routine for primary diagnosis and clarification of bladder 
cancer, remain: ultrasound scan (USG), magnetic reso-
nance imaging (MRI), computed tomography (CT), and en-
doscopic methods (cystoscopy in white light, fluorescence, 
narrowband imaging, and others). The laboratory methods 
that exist are not informative enough, each method has rela-
tive advantages and disadvantages. Each marker has serious 
restrictions, but possibly the complex application will allow 
increasing the diagnostic value in the future. Apparently, the 
use of a palette of markers in connection with imaging tech-
niques will increase the diagnostic capabilities, but it is still 
not clear which elements should be present in such palette. 
Improving the diagnosis of bladder cancer is possible by 
combining the efforts of oncologists, urologists, morpholo-
gists, geneticists, and molecular biologists. Thus, the present 
study confirmed that it is necessary to develop new mark-
ers of bladder cancer or to study the results of the complex 
application of several known markers to increase the value 
of the laboratory diagnosis of primary bladder cancer and 
recurrent.
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